CoChat

Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women

Veldhuis, Johannes D, Patrie, James M, Frick, Kirsten, Weltman, Judith Y, Weltman, Arthur L · 2005 · European Journal of Endocrinology
Cited by 25

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Objective: A recent study indicated that twice-daily s.c. administration of a high dose of recombinant human GHRH-1,44-amide (GHRH) for 90 days can alter body composition in healthy older men. No data establish whether this is also true in postmenopausal women. The present study tests the hypothesis that the same GHRH regimen applied in women will: (i) elevate both IGF-I and GH concentrations; and (ii) reduce abdominal visceral fat mass, augment total body water and enhance functional performance. Design: Ten postmenopausal volunteers underwent baseline study and then received 1 mg GHRH twice daily s.c. for 3 months. Methods: Statistical comparisons were made with preintervention baseline data. Results: GHRH administration stimulated: (i) a mean 98 ± 14% elevation of overnight GH concentrations after administration of the peptide for 1 and 3 months (P < 0.005); (ii) a sustained 71 ± 3.5% rise in IGF-I concentrations over the interval from 2 weeks to 3 months (P < 0.0012); (iii) a 16 ± 7% reduction in abdominal visceral fat mass (P = 0.029) and a 14 ± 5% increase in tri-tiated water space (P < 0.025); (iv) an abbreviation of the times required to walk 30 m (P = 0.015) and ascend two flights of stairs (P = 0.003). Most (70%) subjects experienced local skin reactivity. There were no systemic adverse events. Conclusions: A 3-month regimen of GHRH supplementation in postmenopausal women can stimulate GH and IGF-I production, reduce abdominal visceral fat and improve selected measures of physical performance, while inducing significant local skin reactivity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje.1.02019

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 25

Metadata

Authors
Veldhuis, J. D., Patrie, J. M., Frick, K., Weltman, J. Y., & Weltman, A. L.
Venue
European Journal of Endocrinology
Published
2005-11
Volume
153
Issue
5
Pages
669-677
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2171200727
Cited by
25
References
7
FWCI
1.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women. https://app.cochat.ai/papers/10.1530/eje.1.02019
The paper
Veldhuis, J. D., Patrie, J. M., Frick, K., Weltman, J. Y., & Weltman, A. L. (2005). Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women. European Journal of Endocrinology. https://doi.org/10.1530/eje.1.02019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.